A Bill to require the Secretary of State to seek licences for off-patent drugs in new indications; to require the National Institute for Health and Care Excellence to conduct technology appraisals for off-patent drugs in new indications; and for connected purposes.
House of Commons
Nick Thomas-SymondsLabour (Co-op)
13 May 2016
May contain errors — check source documents for definitive information.
The Off-patent Drugs Bill would require the Secretary of State to seek licences to use off-patent medicines for new medical indications. It would also require NICE to carry out technology appraisals for these drugs in their new indications. The aim is to widen access to affordable, existing medicines by enabling additional uses within the NHS.
The bill is currently at the 2nd reading stage in the House of Commons; it has not yet progressed to committee stage or to the Lords based on the available information.
Generated 21 February 2026
24 Jun 2015
6 Nov 2015
This Bill has been withdrawn and will not progress any further.
The Bill was presented to Parliament through the ballot procedure on 24 June 2015. This is known as the first reading and there was no debate on the Bill at this stage.
The debate on second reading on Friday 6 November 2015 was adjourned.
No recorded votes for this bill yet.
